Patient P-01858
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
88%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −27% vs expected — Dietary Support Protocol NP-02
- Day 46 SC-12 recommended — Supportive Compound SC-12
- Day 47 Patient accepted — Started SC-12 in the companion
- Day 48 Tolerance state changed — Unstable → Improving
- Day 53 GI symptom burden −23% vs expected — Supportive Compound SC-12
- Day 54 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 59 Tolerance state changed — Unstable → Improving
- Day 70 ME-01 recommended — Monitoring Escalation ME-01
- Day 71 Patient accepted — Started ME-01 in the companion
- Day 74 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 54.
Primary contributors, last 14 days
- Inflammatory activity+11
- GI instability+6
- Toxicity+6
- Treatment adherence-3
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −27%
- Supportive Compound SC-12Day 46Result: symptom burden −23%
- Monitoring Escalation ME-01Day 70Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
86%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion45/100
improving · -6.8 vs previous 14 d
Toxicity
Blood45.5/100
worsening · +4.8 vs previous 14 d
Sleep quality
Wearable29.1/100
stable · -1.0 vs previous 14 d
Energy level
Daily log3.3/10
stable · +0.1 vs previous 14 d
Stress level
Daily log5.8/10
stable · -0.2 vs previous 14 d
Steps
Wearable4,083
improving · +385 vs previous 14 d
Adherence
Companion47.8 %
worsening · -5.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 51 from the failing basin, 40 from restoration.
Would help
Would not help
- Keep fat lowGI +4.7 next day on high-intake days · n 19
- Keep histamine lowGI +4 next day on high-intake days · n 20
- Keep simple carbs lowGI +4 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+4.7detractor · 95%
- Histamine load+4detractor · 95%
- Simple carbohydrates+4detractor · 95%
- Alcohol-1.6no signal · 39%
- Spicy / capsaicin+0.7no signal · 15%
- Insoluble fibre-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 46
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
- Autonomic recovery ↓45
- WearableResting HR 73 bpm
- WearableShort sleep window
- Mucosal barrier integrity ↓40
- DNAFUT2 non-secretor lowers mucosal fucosylation
- WearableSleep 6.1 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.4 · butyrate capacity 37/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 50 ms
- Sleep
- 6.1 h
- Steps
- 5,953
- Resting HR
- 73 bpm
Daily log: GI score 45, nutritional resilience 49, adherence 48.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01438 | 49% | S14 | GI-04 | improved | 56 |
| P-01657 | 48% | S14 | GI-04 | improved | 62 |
| P-01627 | 43% | S14 | GI-04 | improved | 54 |
| P-01647 | 43% | S14 | GI-04 | improved | 64 |
| P-01543 | 42% | S14 | GI-04 | improved | 54 |
| P-01588 | 42% | S14 | GI-04 | improved | 57 |
| P-01706 | 42% | S14 | GI-04 | improved | 55 |
| P-01617 | 41% | S14 | SC-12 | improved | 50 |
| P-01842 | 41% | S14 | NP-02 | improved | 55 |
| P-01365 | 40% | S14 | SC-12 | improved | 49 |
| P-01544 | 40% | S15 | GI-04 | improved | 50 |
| P-01624 | 40% | S14 | GI-04 | improved | 52 |